The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe and effective for patients with treatment-resistant depression — the latest attempt by researchers to rigorously evaluate psychedelic drugs’ role in treating conditions like depression, anxiety, and post-traumatic stress disorder.
In the Phase 2 trial, the findings of which were detailed in Nature Medicine, patients who took extended release ketamine tablets at a 180-milligram dosage twice weekly showed a “statistically significant and clinically meaningful improvement in depressive symptoms” compared to a placebo. Other dosages saw less of an impact.
The study, sponsored by New Zealand-based Douglas Pharmaceuticals, is a step toward gathering evidence that could eventually be presented to federal regulators in search of approval for depression treatment, though researchers would still need to complete much larger studies first.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect